Intensification of Early-Phase Therapy to Diminish the Prognostic Effect of Myeloid Antigen Expression in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia: A Report from the JPLSG MLL-10 Trial

Intensification of Early-Phase Therapy to Diminish the Prognostic Effect of Myeloid Antigen Expression in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia: A Report from the JPLSG MLL-10 Trial

Background KMT2A-rearranged acute lymphoblastic leukemia (KMT2A-r ALL) is a rare and dismal disease in infants. Despite restriction of the indication of allogeneic hematopoietic stem cell transplantation to the high-risk group (patients aged

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2021-11, Vol.138 (Supplement 1), p.2384-2384
Hauptverfasser: Arakawa, Yuki, Ishihara, Takashi, Miyamura, Takako, Deguchi, Takao, Sanada, Masashi, Hori, Toshinori, Yamada, Tomomi, Aoki, Yuki, Ishimaru, Sae, Takachi, Takayuki, Yano, Mio, Sasaki, Shinya, Saito, Akiko M, Manabe, Atsushi, Horibe, Keizo, Imamura, Toshihiko, Tomizawa, Daisuke
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background KMT2A-rearranged acute lymphoblastic leukemia (KMT2A-r ALL) is a rare and dismal disease in infants. Despite restriction of the indication of allogeneic hematopoietic stem cell transplantation to the high-risk group (patients aged
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2021-145955